Preterm Delivery Prevention in Twins With Progesterone
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Twin pregnancies have very high preterm delivery rate. Until now, no RCT has proven benefit
of progesterone in this population. In contrast, singleton pregnancies are treated with this
hormone. The objective is to compare 180mg/day progeterone vaginal gel with 180mg/day with
placebo, from 18 weeks to 34 weeks. The sample size was calculated and 213 cases in each
group are needed to demonstrate a reduction of preterm delivery <34weeks from 13% to 7%.
Phase:
Phase 4
Details
Lead Sponsor:
Universidad del Desarrollo
Collaborators:
Hospital Padre Hurtado Hospital San Borja-Arriaran